Asia
A new high-resolution approach using portable DNA sequencers provides a more complete genomic picture of antibiotic resistance in gut bacteria
TLC announced financial results for the second quarter ended June 30, 2019, and provided a business update.
Teva Pharmaceuticals, Endo Pharmaceuticals and Taikoku Pharma entered into settlement agreements with the State of California for a total of almost $70 million. The settlements were over non-competitive, inter-company deals that prevented cheaper drugs from entering the market.
The Tribune India has recently announced that the Department of Biotechnology will be training “unemployed youth in tools and techniques in the area of biotechnology within a period of three years.”
ASLAN Pharmaceuticals, a clinical-stage oncology and immunology focused biopharma company, announced that Andrew Howden has been elected as non-executive Chairman of the Board.
A number of companies reported clinical trial data last week. Here’s a look.
SGX-listed Singapore eDevelopment Ltd is pleased to announce the results of clinical trials conducted on Laetose, a low-glycemic, naturally modified sugar, developed by its U.S. biomedical subsidiary Global BioLife Inc..
Despite the approval, Samsung Bioepis’ Hadlima will not be available in the U.S. until 2023, due to licensing deals with AbbVie, the maker of Humira.
For LENVIMA plus KEYTRUDA Combination Treatment as Potential First-Line Treatment of Patients with Advanced Unresectable Hepatocellular Carcinoma Not Amenable to Locoregional Treatment
Researchers with the Weizmann Institute of Science worked with mice with an ALS-like disease. They found that the course of the disease slowed after the mice received specific strains of gut microbes or substances that were secreted by the microbes. The results suggest that the microbiome may play a regulatory role in people with ALS.
PRESS RELEASES